当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
SHINGRIX, Zoster Vaccine Recombinant, Adjuvanted
申请企业
GlaxoSmithKline Biologicals
药品名称
SHINGRIX, Zoster Vaccine Recombinant, Adjuvanted
承诺描述
A targeted safety study, EPI-ZOSTER-032 VS (209696), to evaluate the safety of Shingrix in adults =65 years of age in the United States.
报告接收日期
2020/12/21 0:00:00